Antagonists of il17c for the treatment of inflammatory disorders

Abstract

The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.

1 . An isolated antibody or antibody fragment specific for IL 17C for use in the treatment of an inflammatory disorder, wherein said inflammatory disorder is selected from pulmonary inflammation, psoriasis, rheumatoid arthritis and COPD (chronic obstructive pulmonary disease), and wherein IL17C consists of amino acids of SEQ. ID No.: 181. 
     
     
         2 - 3 . (canceled) 
     
     
         4 . An isolated antibody or antibody fragment according to  claim 1 , wherein said antibody blocks the binding of IL17C to IL17RE. 
     
     
         5 . An isolated antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment cross-competes with an antibody or antibody fragment comprising 6 CDRs defined by Kabat,
 wherein said antibody or antibody fragment comprises an HCDR1 of Seq. ID: 1, an HCDR2 of Seq. ID: 2, an HCDR3 of Seq. ID: 3, an LCDR1 of Seq. ID: 4, an LCDR2 of Seq. ID: 5 and an LCDR3 of Seq. ID: 6 (MOR12740), or   an HCDR1 of Seq. ID: 31, an HCDR2 of Seq. ID: 32, an HCDR3 of Seq. ID: 33, an LCDR1 of Seq. ID: 34, an LCDR2 of Seq. ID: 35 and an LCDR3 of Seq. ID: 36 (MOR12743), or   an HCDR1 of Seq. ID: 41, an HCDR2 of Seq. ID: 42, an HCDR3 of Seq. ID: 43, an LCDR1 of Seq. ID: 44, an LCDR2 of Seq. ID: 45 and an LCDR3 of Seq. ID: 46 (MOR12744), or   an HCDR1 of Seq. ID: 51, an HCDR2 of Seq. ID: 52, an HCDR3 of Seq. ID: 53, an LCDR1 of Seq. ID: 54, an LCDR2 of Seq. ID: 55 and an LCDR3 of Seq. ID: 56 (MOR12745), or   an HCDR1 of Seq. ID: 61, an HCDR2 of Seq. ID: 62, an HCDR3 of Seq. ID: 63, an LCDR1 of Seq. ID: 64, an LCDR2 of Seq. ID: 65 and an LCDR3 of Seq. ID: 66 (MOR12746), or   an HCDR1 of Seq. ID: 71, an HCDR2 of Seq. ID: 72, an HCDR3 of Seq. ID: 73, an LCDR1 of Seq. ID: 74, an LCDR2 of Seq. ID: 75 and an LCDR3 of Seq. ID: 76 (MOR12751), or   an HCDR1 of Seq. ID: 91, an HCDR2 of Seq. ID: 92, an HCDR3 of Seq. ID: 93, an LCDR1 of Seq. ID: 94, an LCDR2 of Seq. ID: 95 and an LCDR3 of Seq. ID: 96 (MOR12754), or   an HCDR1 of Seq. ID: 141, an HCDR2 of Seq. ID: 142, an HCDR3 of Seq. ID: 143, an LCDR1 of Seq. ID: 144, an LCDR2 of Seq. ID: 145 and an LCDR3 of Seq. ID: 146 (MOR12759), or   an HCDR1 of Seq. ID: 151, an HCDR2 of Seq. ID: 152, an HCDR3 of Seq. ID: 153, an LCDR1 of Seq. ID: 154, an LCDR2 of Seq. ID: 155 and an LCDR3 of Seq. ID: 156 (MOR12760), or   an HCDR1 of Seq. ID: 161, an HCDR2 of Seq. ID: 162, an HCDR3 of Seq. ID: 163, an LCDR1 of Seq. ID: 164, an LCDR2 of Seq. ID: 165 and an LCDR3 of Seq. ID: 166 (MOR12761), or   an HCDR1 of Seq. ID: 171, an HCDR2 of Seq. ID: 172, an HCDR3 of Seq. ID: 173, an LCDR1 of Seq. ID: 174, an LCDR2 of Seq. ID: 175 and an LCDR3 of Seq. ID: 176 (MOR12762).   
     
     
         6 . An isolated antibody or antibody fragment according to  claim 1  wherein said antibody or fragment thereof is a monoclonal antibody. 
     
     
         7 . The antibody or antibody fragment of  claim 6 , wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment. 
     
     
         8 . The antibody or antibody fragment of  claim 6 , wherein said antibody or antibody fragment comprises a human heavy chain constant region and a human light chain constant region. 
     
     
         9 . The antibody or antibody fragment of  claim 6 , wherein said antibody is of the IgG isotype. 
     
     
         10 . The antibody or antibody fragment of  claim 6 , wherein said antibody fragment is selected from the group consisting of a Fab, F(ab2)′, F(ab) 2 ′, scFV.